Clinically relevant concurrent BRAF and MEK inhibition alters differentiation states and sensitizes BRAF V600E-mutated high-grade gliomas to immune checkpoint blockade https://www.biorxiv.org/content/10.1101/2023.02.03.526065v1?med=mas
Clinically relevant concurrent BRAF and MEK inhibition alters differentiation states and sensitizes BRAF V600E-mutated high-grade gliomas to immune checkpoint blockade https://www.biorxiv.org/content/10.1101/2023.02.03.526065v1?med=mas